Reports Q2 revenue $10.4M, consensus $12.56M. As of June 30, 2023, Sutro had cash, cash equivalents and marketable securities of $358.3M, as compared to $251.5M as of March 31, 2023, and approximately 0.7M shares of Vaxcyte common stock with a fair value of $33.3M, which together provide a projected cash runway into the first half of 2025, based on current business plans and assumptions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on STRO: